Table 1.
Small molecule inhibitors of protein-protein interactions currently in clinical trials for hematologic malignancies
| Drug candidate | Target protein | Indication | Status | Reference |
|---|---|---|---|---|
| RO5045337 | MDM2-p53 | Hematologic neoplasms (leukemia) | Phase 1 | (194) |
| PRI-724 | CBP/beta-catenin | AML, CML | Phase 1/2 | (195) |
| TL32711 | SMAC mimetic | AML, ALL, MDS | Phase 1/2 | (196) |
| LCL161 | SMAC mimetic | Multiple myeloma | Phase 2 | (197) |
| ABT-263 | Bcl-2-BH3 | Hematological cancers (lymphoma, leukemia) | Phase 1/2 | (198) |
| GX15-070 | Bcl-2 family – BH3 | Hematological cancers (lymphoma, leukemia) | Phase 1/2 | (199) |
| GSK525762 | BET bromodomains | Hematologic Malignancies | Phase 1 | (88) |
| OTX015 | BET bromodomains | Hematologic Malignancies | Phase 1 | NCT01713582a |
| CPI-0610 | BET bromodomains | Lymphoma | Phase 1 | NCT01949883a |
a
Clinical trial identifier.